Close menu




October 15th, 2021 | 10:10 CEST

MorphoSys, Sativa Wellness Group, CureVac: Healthcare investments of tomorrow

  • Healthcare
Photo credits: pixabay.com

The healthcare sector is facing a reassessment. For years, especially in Germany, health care has been "fiddled with" - a reform here, a change there, but in basic terms, little has changed in the system in recent years. With the new federal government, things could start to move. Regardless of ideological trench warfare, observers can state, especially under the impression of the pandemic, that innovative treatment methods and preventive care are the most important trends for the future, along with the digitization of the healthcare system. In this context, we present three companies and highlight their opportunities.

time to read: 2 minutes | Author: Nico Popp
ISIN: MORPHOSYS AG O.N. | DE0006632003 , SATIVA WELLNESS GROUP INC | CA80403E1043 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:


    MorphoSys: Here's how investors can act

    When it comes to innovative treatment methods, many private investors think of MorphoSys. The Company has been accompanying German investors for years. Above all, MorphoSys impresses with its antibody library, which is the largest of its kind in the world. In addition to cancer, the Martinsried-based Company also focuses on Alzheimer's disease and rheumatism. MorphoSys caused a stir with lower revenues and a loss of just over EUR 20 million in the first half of the year. Despite - or perhaps because of - the weak figures, the Company decided to acquire in the summer: With Constellation Pharmaceuticals, the Company is strengthening its pipeline of potential cancer drugs.

    Having good cards in hand is vital for MorphoSys. The share price lost almost 60% last year, and over the previous three months alone, it fell by around 37%. Since the big breakthroughs have failed to materialize in recent months, one or the other investor may have switched to the new listed competitor of BioNTech. Although these shares are also volatile, there is always an upward trend in between the turbulence. MorphoSys lacks this dynamism completely. The stock is currently of little interest.

    Sativa Wellness Group: Turnaround stock stands on strong legs

    Sativa Wellness Group is more active in the field of self-therapy and wellness. The Company is built on the three pillars of cannabidiol (CBD), laboratory services related to the active ingredient from the hemp plant, and other wellness products. Studies by the Brightfield Group state that the British market for CBD products can grow at double-digit rates in the coming years. Since Sativa Wellness is already positioned in the market and scores with good quality at fair prices, the Company could secure a share of this market.

    The latest figures also show that Sativa Wellness is well received by customers. The first quarter was the best in terms of sales. In the second quarter, the Company even went one better and scored with a positive cash flow. This cash flow is intended to enable the Company to seize inorganic growth opportunities in the future. Most recently, Sativa Wellness announced plans to offer telemedicine consulting services through its wellness division. This area could also be promising given the growing awareness of health. The stock has been trading sideways for months, eking out an existence as a penny stock. However, speculative investors should put the stock on the watch list given the encouraging figures and the expansion into new business areas.

    A bitter pill for CureVac

    The fact that new active ingredients and processes in the biotech sector always carry a speculative element is demonstrated by the CureVac share. After failing to bring a vaccine against Covid-19 to market, the stock began to sell-off. Even the hope of future success is currently not priced in by the market. The share is currently trading around 18% lower than a year ago. The three short-term excursions above the EUR 100 mark are a warning to investors who expect too much from the share. Currently, the air is out, and even lower prices are possible below EUR 40.


    The fate of CureVac and the long dry spell of MorphoSys show that the development of new active substances is anything but easy. On the other hand, Sativa Wellness is well positioned with its CBD products and the mainstay of having one of the leading laboratories around the active ingredient in its portfolio. While the companies are hardly comparable, the recent turnaround at Sativa could soon appeal to more investors.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Stefan Feulner on April 29th, 2022 | 11:16 CEST

    BioNTech, NervGen, Sanofi - The rebound is on the way

    • Biotechnology
    • Healthcare

    Uncertainties remain. Admittedly, infection figures are falling in the Corona pandemic and should ensure a quiet summer in this respect. In addition to inflation remaining at a high level, the Ukraine conflict moved to the front news pages. It has caused panic and strong sales on the stock markets in recent weeks. After the DAX marked another interim low at around 13,500 points yesterday, the stock market barometer turned around but is struggling with the psychologically important mark at 14,000 points. Now the quarterly season has begun, which could provide positive impetus. Commerzbank and Deutsche Bank started it off and were quite convincing.

    Read

    Commented by Nico Popp on March 17th, 2021 | 07:25 CET

    Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

    • Healthcare

    The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

    Read

    Commented by Nico Popp on January 19th, 2021 | 10:50 CET

    Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?

    • Healthcare

    We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.

    Read